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Oral Delivery of ACE2/Ang-(1–7) Bioencapsulated in Plant Cells Protects Against
Experimental Uveitis and Autoimmune Uveoretinitis
Abstract
Hyperactivity of the renin-angiotensin system (RAS) resulting in elevated Angiotensin II (Ang II)
contributes to all stages of inflammatory responses including ocular inflammation. The discovery of
angiotensin-converting enzyme 2 (ACE2) has established a protective axis of RAS involving ACE2/Ang(1–7)/Mas that counteracts the proinflammatory and hypertrophic effects of the deleterious ACE/AngII/
AT1R axis. Here we investigated the hypothesis that enhancing the systemic and local activity of the
protective axis of the RAS by oral delivery of ACE2 and Ang-(1–7) bioencapsulated in plant cells would
confer protection against ocular inflammation. Both ACE2 and Ang-(1–7), fused with the non-toxic
cholera toxin subunit B (CTB) were expressed in plant chloroplasts. Increased levels of ACE2 and Ang(1–7) were observed in circulation and retina after oral administration of CTB-ACE2 and Ang-(1–7)
expressing plant cells. Oral feeding of mice with bioencapsulated ACE2/Ang-(1–7) significantly reduced
endotoxin-induced uveitis (EIU) in mice. Treatment with bioencapsulated ACE2/Ang-(1–7) also
dramatically decreased cellular infiltration, retinal vasculitis, damage and folding in experimental
autoimmune uveoretinitis (EAU). Thus, enhancing the protective axis of RAS by oral delivery of ACE2/Ang(1–7) bioencapsulated in plant cells provide an innovative, highly efficient and cost-effective therapeutic
strategy for ocular inflammatory diseases.
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Oral Delivery of ACE2/Ang-(1–7) Bioencapsulated
in Plant Cells Protects against Experimental
Uveitis and Autoimmune Uveoretinitis
Pollob K Shil1, Kwang-Chul Kwon2, Ping Zhu1, Amrisha Verma1, Henry Daniell2 and Qiuhong Li1
1
Department of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA; 2Department of Biochemistry, School of Dental
Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA;

Hyperactivity of the renin-angiotensin system (RAS)
resulting in elevated Angiotensin II (Ang II) contributes
to all stages of inflammatory responses including ocular
inflammation. The discovery of angiotensin-converting
enzyme 2 (ACE2) has established a protective axis of RAS
involving ACE2/Ang-(1–7)/Mas that counteracts the proinflammatory and hypertrophic effects of the deleterious
ACE/AngII/AT1R axis. Here we investigated the hypothesis that enhancing the systemic and local activity of the
protective axis of the RAS by oral delivery of ACE2 and
Ang-(1–7) bioencapsulated in plant cells would confer
protection against ocular inflammation. Both ACE2 and
Ang-(1–7), fused with the non-toxic cholera toxin subunit
B (CTB) were expressed in plant chloroplasts. Increased
levels of ACE2 and Ang-(1–7) were observed in circulation
and retina after oral administration of CTB-ACE2 and Ang(1–7) expressing plant cells. Oral feeding of mice with
bioencapsulated ACE2/Ang-(1–7) significantly reduced
endotoxin-induced uveitis (EIU) in mice. Treatment
with bioencapsulated ACE2/Ang-(1–7) also dramatically
decreased cellular infiltration, retinal vasculitis, damage
and folding in experimental autoimmune uveoretinitis
(EAU). Thus, enhancing the protective axis of RAS by oral
delivery of ACE2/Ang-(1–7) bioencapsulated in plant cells
provide an innovative, highly efficient and cost-effective
therapeutic strategy for ocular inflammatory diseases.
Received 28 April 2014; accepted 9 September 2014; advance online
publication 14 October 2014. doi:10.1038/mt.2014.179

INTRODUCTION
Retinal inflammation is one of the major causes of visual impairment and is also a key underlying factor for a range of retinal diseases. Uveitis is a sight threatening intraocular inflammatory
disorder caused by infectious agents, autoimmune mechanisms,
exposure to toxins and many other unknown factors1 and has been
estimated to account for 5–15% of all cases of total blindness in the
United States.2 Endotoxin-induced uveitis (EIU) is an animal model
of acute ocular inflammation induced by the administration of
lipopolysaccharide (LPS).3 LPS enhances the expression of various

inflammatory mediators resulting in the breakdown of blood-ocular
barriers and infiltration of inflammatory cells in ocular tissues which
contribute to the development of EIU.3 Experimental autoimmune
uveoretinitis (EAU) is an animal model of autoimmune uveitis that
resembles human uveitis.4 It is an organ specific, T-cell mediated
autoimmune disease that targets the neural retina and related tissues. Immunization of rodents with retinal antigen such as interphotoreceptor retinoid binding protein (IRBP) to induce EAU is a
widely used experimental model to investigate the immunopathogenesis of autoimmune uveitis.4 The clinical, biochemical, immunological and histological characteristics make EIU and EAU suitable
in vivo models to evaluate the efficacy of therapeutics for the treatment of inflammatory ocular diseases in humans.3,4
The renin-angiotensin system (RAS) plays an important role
not only in the cardiovascular homeostasis, but also in the pathogenesis of inflammation and autoimmune dysfunction in which
Angiotensin II (Ang II) functions as the potent proinflammatory
effector via Angiotensin Type 1 receptor (AT1 receptor). Most
components of RAS have been identified in every organ including
the eye. The tissue-specific RAS is believed to exert diverse physiological effects locally independent of circulating Ang II.5 Discovery
of angiotensin-converting enzyme 2 (ACE2) has resulted in the
establishment of a novel axis of RAS involving ACE2/Ang-(1–7)/
Mas.6 ACE2 is a zinc-metallopeptidase able to cleave Ang II to
form Angiotensin-(1–7) [Ang-(1–7)]. Ang-(1–7), a biologically
active peptide, binds to a G-protein coupled receptor, Mas, and
activates signaling pathways that counteract the effects of Ang
II.6 Thus, the ACE2/Ang-(1–7)/Mas axis has emerged as a critical regulator of Ang II/AT1R signaling. Several studies have shown
that ACE2/Ang-(1–7)/Mas axis also influences inflammatory
responses and negatively modulates leukocyte migration, cytokine
expression and release, and fibrogenic pathways.7 We have recently
shown that increased expression of ACE2 and Ang-(1–7) reduced
diabetes-induced retinopathy and inflammation in both mouse
and rat models of diabetic retinopathy,8 activation of endogenous
ACE2 activity reduced endotoxin-induced uveitis,9 providing the
proof-of-concept that enhancing the protective axis of RAS is a
promising therapeutic strategy for ocular inflammatory diseases.
However, the ability to deliver drugs efficiently to the retina
or the brain remains a key challenge due to anatomic barriers
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and physiological clearance mechanisms.10 Plant chloroplast
genetic engineering system to express therapeutic proteins is
emerging as a highly efficient, cost-effective approach for therapeutic interventions of many pathologic conditions.11 In contrast
to current protein production systems (mammalian, yeast, or
bacteria), the transplastomic system requires no complex production/purification steps.11 Current biopharmaceuticals are not
affordable to more than half of the global population because
of use of prohibitively expensive production, purification and
delivery systems.11 However, chloroplasts produce the same
biopharmaceuticals at a significantly lower cost by eliminating
fermentation, purification, cold chain and sterile delivery systems. Such cGMP facilities to produce plants for human clinical
studies are already in use in the US (e.g., Fraunhofer, Delaware,
Kentucky Bioprocessing, etc.). Ultimately, the therapeutic proteins will be provided to patients as capsules after lyophilization
of plant cells, facilitating prolonged storage at room temperature. In addition, bioencapsulation of therapeutic proteins
within plant cell walls enable oral delivery by their protection in
the digestive system.11,12 The bioencapsulated proteins that pass
through the stomach are released in the intestine with the aid
of commensal bacteria.13,14 Bacteria inhabiting the human gut
have evolved to utilize complex carbohydrates in plant cell wall
and are capable of utilizing almost all of plant glycans. So the
gut microbes recognize, import, and digest plant cell wall consisting of cellulose, hemicellulose, and pectin. Up to 10% daily
energy is obtained from polysaccharide fiber via the symbiotic
bacteria living in human gut. These polysaccharides are broken
down to sugars and fermented to short fatty acids then absorbed
by human gut. Therapeutic proteins enter circulation by receptor monosialotetrahexosylganglioside (GM1) mediated delivery
when fused with the non-toxic subunit B of cholera toxin (CTB)
as the transmucosal carrier.11,15–19 The use of CTB as a transmucosal carrier can facilitate the transportation of conjugated proteins into circulation through its strong binding to GM1 because
large mucosal area of human intestine (~1.8–2.7 m2 (ref. 20) facilitates CTB to bind an intestinal epithelium cell up to a maximum
of 15,000 CTB.21 Furthermore, the GM1 gangliosides receptors
are also found in the plasma membranes of most cells, particularly most abundant in the nervous system and retina,22 allowing
efficient uptake of CTB fusion protein in the brain and retinal
cells as observed in our recent study.23
Considering the proven anti-inflammatory actions of ACE2
and Ang-(1–7) and the ability of CTB to cross the epithelial barrier
and facilitate neuronal uptake, we hypothesized that oral delivery
of ACE2 and Ang-(1–7) fused with CTB bioencapsulated in plant
cells will enhance both systemic and local activity of the protective axis of RAS and confer protection against ocular inflammation. In this study, we tested this hypothesis in two mouse models
of ocular inflammation. We observed that oral administration of
CTB-ACE2 and CTB-Ang-(1–7) bioencapsulated in plant cells
reduced ocular inflammation in both EIU and EAU models, providing proof-of-concept that enhancing the protective axis of RAS
by oral delivery of ACE2/Ang-(1–7) bioencapsulated in plant
cells provides an innovative, highly efficient and cost-effective
therapeutic strategy for ocular inflammation such as uveitis and
autoimmuneuveoretinitis.
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RESULTS
Creation of transplastomic plants expressing
CTB-ACE2 and CTB-Ang-(1–7)
The CTB-fused therapeutic genes were cloned into the chloroplast transformation vector, pLD. The hinge site (Figure 1a)
was introduced between CTB and therapeutic proteins to avoid
steric hindrance so as to facilitate proper formation of pentameric structure of CTB fused to therapeutics when expressed in
chloroplasts. Since the pentamer structure of CTB plays critical
role in translocating fusion proteins into epithelial cell via GM1
receptor, the introduction of hinge is required to facilitate to form
proper structure of the CTB fusion proteins. Furin cleavage site
(Figure 1a) is responsible for the release of therapeutic proteins
from CTB after internalization into cells. The furin is ubiquitously present in the body and the consensus cleavage site is well
characterized.24 The introduction of the consensus furin cleavage
site between CTB and the proteins will ensure efficient release
of the therapeutic proteins from CTB in the circulation. For the
site-specific integration of the CTB-ACE2/-Ang-(1–7) expression
cassette into chloroplast genome, the cassette was flanked by trnI
and trnA sequence, which are homologous to endogenous chloroplast sequence. Light regulated strong chloroplast promoter,
PsbA, was used to express the fusion gene. To screen chloroplast transformants, aminoglycoside 3′-adenylyltransferase gene
(aadA) was driven under the control of ribosomal rRNA promoter (Prrn) to disarm the inhibitory action of spectinomycin
on chloroplast translation (Figure 1a). The sequence-confirmed
chloroplast transformation vector was bombarded onto leaf disc
to create the transplastomic plants expressing CTB-ACE2 and
CTB-Ang-(1–7), using biolistic particle delivery system. Shoots
emerged from spectinomycin containing regeneration medium
were investigated for the site specific integration of the expression
cassette into chloroplast genome, using PCR analysis. The specific primer sets were designed to amplify fragments in the size
of ~1.65 kb with 3P/3M for both CTB-ACE2 and CTB-Ang-(1–7),
~4.5 and ~2.2 kb with 5P/2M for CTB-ACE2 and CTB-Ang-(1–7),
respectively, and ~3.0 and ~1.1 kb with 5P/R for CTB-ACE2 and
CTB-Ang-(1–7), respectively. As seen in the Figure 1b,c, the positive shoots displaying the expected right size fragments were subjected to two more rounds of tissue culture under the antibiotic
pressure to achieve homoplasmy. The homoplasmic plants were
confirmed by Southern blot analysis (data not shown), transferred and grown in a temperature- and humidity-controlled
greenhouse. The expression level of CTB-fused therapeutic proteins of mature leaves was measured quantitatively using densitometry and Image J or ELISA with known amount of CTB
proteins to generate standard curve. The level was up to 2.14%
and 8.7% of total leaf protein for CTB-ACE2 and CTB-Ang-(1–7)
at their peak, respectively (data not shown). For consistency of
batches between harvests, the leaf harvests were always done
at evening time around 6 pm to maximize accumulation of the
fusion proteins expressed under the control of light regulated
promoter, psbA which can stay activated during the daylight.
Also, only mature leaves were chosen for harvest to maintain
similar expression levels of the proteins between batches. While
it is difficult to precisely control expression levels at the time of
harvest, dosage is precisely determined after lyophilization and
www.moleculartherapy.org vol. 22 no. 12 dec. 2014
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Figure 1 Creation of transplastomic lines expressing CTB-ACE2 and CTB-Ang-(1–7). (a) Schematic representation of chloroplast transformation
vector containing CTB-ACE2 and Ang-(1–7) expression cassettes. Prrn, rRNA operon promoter; aadA, aminoglycoside 3′-adenylytransferase gene;
PpsbA, promoter and 5′ UTR of psbA gene; CTB, coding sequence of non-toxic cholera B subunit; ACE2 and Ang, coding sequence for Angiotensinconverting enzyme 2 and Angiotensin-(1–7), respectively; TpsbA, 3′ UTR of psbA gene; trnI, isoleucyl-tRNA; trnA, alanyl-tRNA; Amino acid sequence,
hinge, furin cleavage site. Arrows represent primers used to amplify the site-specific integration of the expression cassette. Restriction enzymes used
for Southern blot analysis were indicated as BamHI/BglII for the generation of probe and HindIII for the digestion of genomic DNA. (b,c) PCR analysis of the site specific integration of the transgenes with 3P/3M, 5P/2M, and 5P/R primer sets. M, DNA size marker; UT, untransformed wild-type;
#61–64, CTB-ACE2 transplastomic line; #B2, B4, B6, and B8, CTB-Ang-(1–7) transplastomic lines; PC, CTB-ACE2, and -Ang-(1–7) containing vector.

delivered by varying the weight of lyophilized powder in each
capsule or gavage.

Characterization of CTB-fused therapeutic proteins
expressed in chloroplasts
CTB was used as a carrier to allow therapeutic proteins to pass
through both epithelial and blood–retinal barrier,23 which is
mediated by the interaction between pentameric CTB and GM1
receptor. To investigate the proper folding and assembly of the
pentameric structure of CTB-fused therapeutic proteins in chloroplasts, western blot analysis was performed with CTB-Ang-(1–7).
Proteins were extracted under non-denaturing conditions, followed
by either treatment with or without denaturing agents, prior to running on SDS-acrylamide gel. There was negligible change in band
patterns for oligomeric structures of CTB-Ang-(1–7) when protein
was treated with DTT alone (Figure 2a). In contrast, boiling samples showed dramatic change in band patterns (Figure 2a). This is
consistent with the previous studies on dissociation of CTB pentameric structure.25 Multiple interactions between CTB monomers,
such as 30 hydrogen bonds, 7 salt bridges and hydrophobic interactions, make pentameric structure of CTB highly resistant to the dissociation so the pentamer structure is not affected by denaturants
such as SDS and DTT. However, the structure can be dissociated by
using heat energy. This could be due to the difference in accessibility
of each denaturing agents to their targets. The access of DTT to the
intramolecular disulfide bond of monomer is not easy unless pentameric structure dissociates first, due to the intimate interactions
Molecular Therapy vol. 22 no. 12 dec. 2014

between monomers described above. As expected, both denaturing agents showed no high molecular weight oligomers (pentamer-pentmer interactions), but dimeric and monomeric forms
of CTB-Ang-(1–7) were observed (Figure 2a). The intramolecular disulfide bond of CTB monomer was easily disrupted by DTT
after boiling than either boiling alone or DTT alone (Figure 2a).
Boiling allowed easy access of DTT to the internal disulfide bond by
breaking intimate interactions between CTB monomers (hydrogen
bonds and salt bridges) (Figure 2a). From these results, it is evident
that the disulfide bond of CTB-Ang-(1–7) monomer was properly
formed and the interactions between the monomers of pentameric
structure of CTB-Ang-(1–7) were well established in chloroplasts.
For clinical application, long-shelf life and stability of therapeutic protein expressed in plants are very important for successful and cost-effective treatment. Therefore, lyophilized CTB-fused
therapeutic protein leaves were fully characterized. The weight of
lyophilized leaf is usually reduced by 90–95% as a result of removal
of water from plant cells, leading to more total protein per mg.
Extraction of concentrated proteins from lyophilized leaf materials needs more volume of extraction buffer because the amount of
water lost in the process of lyophilization is slowly reabsorbed by
the dried materials. For quantitation of lyophilized leaf materials,
10 mg of lyophilized powered leaf materials were resuspended in
300 µl extraction buffer in contrast to 100 mg of fresh leaf materials
in the same volume of extraction buffer. Then the extracted total
proteins were used for quantification for comparison between
fresh and lyophilized leaf materials. Western blot analysis for the
2071
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Figure 2 Evaluation of proper formation of pentameric structure and lyophilization for the CTB fusion proteins. (a) Western blot analysis to
investigate the proper folding and assembly of CTB-Ang-(1–7) expressed in chloroplasts. Four micrograms of total leaf protein were loaded for each
lane with (+) or without (−) treatment of denaturing agents. CTB, purified non-toxic cholera B subunit (10 ng); UT, untransformed wild-type; DTT,
100 mmol/l; boiling, incubation of samples in boiling water for 3 minutes; H, homogenate total leaf protein; S, supernatant fraction after centrifugation of the total leaf protein; Arrows and numbers, locations of monomer and oligomers of CTB-Ang-(1–7); P, pentamer-pentamer complexes.
(b) Western blot analysis for the comparison of the level of CTB-Ang-(1–7) in lyophilized (L) and fresh (F) leaves. Equal amount of lyophilized and
fresh leaf material (10 mg) was extracted in same volume (300 µl) of extraction buffer. 1X represents 1 µl of homogenate protein resuspended in
extraction buffer. The samples were boiled in DTT prior to loading on SDS acrylamide gel. Purified CTB standard protein was loaded as indicated
for densitometric analysis. (c,d) Comparison of the level of CTB-Ang-(1–7) and –ACE2 in lyophilized (L) and fresh (F) leaves. Data are means ± SD
of three independent experiments. (e) GM1 binding assay of CTB-ACE2 and -Ang-(1–7). Extracted total protein samples were serially diluted up to
10 pg/ul, which means 11 on the Y axis, and used for GM1 binding assay. The binding affinity was read at 450 nm then an absorbance of ≥0.1 after
background signal substraction was determined as positive. Two and three different batches were examined for fresh and lyophilized leaf materials,
respectively, and indicated as black diamond. CTB, purified non-toxic cholera B subunit (black circle); UT, untransformed wild-type (black triangle);
F, fresh; L, lyophilized; 12 and 15, 12- and 15-month storage at room temperature. *P < 0.001 (versus fresh); #P < 0.001 (versus WT).

CTB-Ang-(1–7) showed that the band patterns between fresh and
3-month-old lyophilized leaf materials were identical (Figure 2b),
confirming stability during lyophilization and prolonged storage
at room temperature. As seen in the blot, twenty-time less lyophilized protein sample loaded showed similar band intensities to
fresh leaf proteins (Figure 2b). The quantity of CTB-Ang-(1–7)
in fresh and lyophilized leaves was measured using immunoblots
(Figure 2b) and Image J software. The quantity of lyophilized
CTB-Ang-(1–7) increased 14.3 times in lyophilized leaves when
compared to fresh leaves (Figure 2c). The lyophilized CTB-ACE2
leaves showed 20.5-fold more CTB-ACE2 than fresh leaves when
quantified using ELISA (Figure 2d).
In this study, we observed that there was no damage or loss of
the fusion protein (Figure 2b) under the optimized lyophilization
conditions. Moreover, the intactness of the pentameric structure
2072

of the lyophilized CTB-fused proteins was well preserved up to
15 months at room temperature, as confirmed in GM1 binding
assay which showed binding affinity of the lyophilized CTB-fused
proteins to GM1 as compared to respective positive control, CTB
(Figure 2e). Taken together, the homoplasmic transplastomic
plants expressing CTB-ACE2 and -Ang-(1–7) were created and
the fusion protein was properly expressed, folded, and assembled
in chloroplasts. The folding, assembly and functionality of therapeutic proteins were well preserved in lyophilized leaves.
ACE2 activity assay using protein extracts isolated from plant
leaves showed that plant cell expressed human ACE2 is enzymatically active (Figure 3a). To investigate the in vivo potential
of CTB-ACE2 and CTB-Ang-(1–7) to cross the intestinal barrier
and tissue uptake, wild-type (WT) C57Bl/6J mice were fed with
either fresh (F, ~500 mg/mouse), or tenfold less lyophilized (L,
www.moleculartherapy.org vol. 22 no. 12 dec. 2014
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and monocytes in the iris, ciliary body, anterior chamber, and posterior chamber of the eye. Sagittal sections were stained with H&E
and examined under bright field microscope. The histological evaluation of LPS injected eyes from mice fed with WT leaf revealed
severe signs of uveitis with massive infiltration of inflammatory
cells into the iris and ciliary body (ICB) (140 ± 21 cells/section),
anterior chamber (265 ± 52 cells/section) and the posterior chamber (202 ± 37 cells/section) (Figure 4). Prophylactic treatment with
CTB-ACE2 showed significantly diminished uveitis and reduced
number of inflammatory cells into the ICB (60 ± 09 cells/section),
anterior chamber (96 ± 15 cells/section) and also into the posterior
chamber (82 ± 15 cells/section). Similar results were observed in
ICB (70 ± 15 cells/section), anterior chamber (114 ± 36 cells/section)
and the posterior chamber (28 ± 15 cells/section) when animals pretreated with CTB-Ang-(1–7) expressed leaf material (Figure 4).
The therapeutic effect of different doses of CTB-ACE2 in EIU
was evaluated using lyophilized leaf materials (Supplementary
Materials and Methods). Oral feeding of lyophilized CTB-ACE2
at 50 mg/day significantly prevented inflammatory cell infiltration

~50 mg/mouse) CTB-ACE2, or control untransformed (WT) leaf
materials for three days, mice were sacrificed at 5 hours after the
last gavage. Circulatory and retinal ACE2 and Ang-(1–7) levels
were measured by ACE2 activity assay, EIA and Western blotting (Figure 3). ACE2 protein can be detected in both serum and
retina 5 hours after oral gavage (Figure 3b). Oral administration
of either fresh frozen (F) or lyophilized (L) CTB-ACE2 transplas
tomic leaf materials resulted in an increase of ~40 and >20% in
ACE2 enzymatic activity in serum and retina respectively when
compared to WT leaf fed mice (Figure 3c). There was a 15%
increase in plasma and nearly 50% increase in Ang-(1–7) peptide
level in the retina in CTB-Ang-(1–7) expressed leaf material fed
group, detected by Ang-(1–7) specific EIA kit (Figure 3d).

Oral administration of bioencapsulated CTB-ACE2
and CTB-Ang-(1–7) reduced the infiltration of
inflammatory cells induced by EIU
We next examined the effects of ACE2 and Ang-(1–7) on endotoxin-induced infiltration of inflammatory cells such as leucocytes
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Figure 4 Histological evaluation of EIU mice. The mice were orally administered with wild-type, CTB-ACE2 and CTB-Ang-(1–7) expressed leaf material for five days before LPS (25 ng/eye) injection. Eyes were enucleated 24 hours after LPS injection, fixed and processed for paraffin sections and
stained with H&E. (a) Representative photographs of the iris ciliary body, anterior chamber and posterior chamber. Original magnifications 20×. Bar
= 50 µm. (b) Histopathologic score evaluation. Inflammatory cells per section in the iris ciliary body, anterior chamber and posterior chamber were
counted from H&E stained paraffin sections from eyes at 24 hours after EIU induction. Values on y-axis represent no. of infiltrating inflammatory cells/
section. Results are given as mean + SD; (n = 6 per group); *P < 0.05 (versus WT+LPS group).

into the iris and ciliary body, anterior chamber and posterior
chamber to the same extent as the fresh leaf material at 500 mg/
day; CTB-ACE2 feeding at 25 mg/day had moderate but significant
protection, whereas 12.5 mg/day did not show any protective effect
in EIU (Supplementary Figure S1).

Oral administration of bioencapsulated CTB-ACE2
and CTB-Ang-(1–7) reduced the expression of the
inflammatory cytokinesin EIU eyes
To investigate the effects of ACE2 and Ang-(1–7) on the expression of inflammatory cytokines in EIU eyes, the mRNA levels of
cytokine genes were determined by real-time RT-PCR. In the WT
leaf fed mice, LPS caused a significant increase in mRNA levels
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of Interleukin-6 (IL-6), Interleukin-1β (IL-1β), Tumor necrosis
factor-α (TNF-α) and vascular endothelial growth factor (VEGF)
and this increase was reduced in mice fed with ACE2/Ang-(1–7)
leaf materials (Figure 5a). These results suggest that ACE2 and
Ang-(1–7) reduced infiltration of inflammatory cells and cytokine
production through suppressing their gene expressions during EIU.
To investigate the molecular mechanisms of leucocyte recruitment,
the mRNA levels of intercellular adhesion molecule-1 (ICAM-1)
and monocyte chemoattractant protein (MCP-1) were measured
in EIU eyes. The expression of both ICAM-1 and MCP-1 was significantly increased in LPS induced EIU eyes in mice treated with
WT leaf material and was significantly reduced in mice fed with
CTB-ACE2 or CTB-Ang-(1–7) (Figure 5a).
www.moleculartherapy.org vol. 22 no. 12 dec. 2014
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The impact of oral administration of bioencapsulated
CTB-ACE2 and CTB-Ang-(1–7) on the expression of
the retinal RAS genes during EIU
In addition to circulating RAS, all components of RAS have been
detected in the retina and a local retina RAS may play an important role in modulating local immune responses.8,9,26 We compared
ocular mRNA levels of the key RAS genes in animals fed with
ACE2 and Ang-(1–7) expressing leaf materials as well as untransformed WT leaf materials. LPS-induced EIU resulted in increased
expression of both ACE and ACE2, however prominent increase in
ACE (more than fourfold increase) than ACE2 (less than twofold
increase), resulted in increased ratio of ACE/ACE2 (Figure 5b).
Molecular Therapy vol. 22 no. 12 dec. 2014

CTB-ACE2 or CTB-Ang-(1–7) oral feeding normalized the shift
of ACE/ACE2 ratio (Figure 5b). The mRNA levels for receptors
for Ang II (AT1Ra, AT1Rb) were also increased in EIU mice
fed with control leaf material (~4-fold and 1.7-fold respectively)
(Figure 5b), both of which were significantly decreased in mice
fed with CTB-ACE2 or CTB-Ang (1–7). There was a slight but significant increase in Mas, the receptor for Ang-(1–7). Interestingly
the Mas mRNA level in the retina was further increased in mice
fed with CTB-ACE2 (approximately twofold increase), and even
more increase in mice fed with CTB-Ang-(1–7) leaf material
(approximately threefold increase) (Figure 5b), suggesting a possible feed-forward regulatory response in local retinal RAS.
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Oral delivery of bioencapsulated CTB-ACE2 and CTBAng-(1–7) attenuated autoantigen induced uveoretinitis
Experimental autoimmune uveoretinitis was induced in an autoimmune susceptible B10.RIII mouse strain by active immunization
using a peptide derived from the retinal protein IRBP.27 Evident
inflammatory reactions such as mild to severe vasculitis, focal
lesions, large confluent lesions, retinal hemorrhages and folding,
corneal edema etc., were observed in WT leaf fed animals by fundoscopy examination at day 14 of EAU induction (Figure 6a, i,ii).
However, mice fed with CTB-ACE2 or -Ang-(1–7) leaf materials
showed significantly reduced inflammatory reactions (Figure 6a,
iii–vi). The clinical scoring, using the criteria reported by Copland
et al.,28 showed that eyes from CTB-ACE2 or CTB-Ang-(1–7) fed
animals had significantly improved clinical scores (EAU grade,
2.3 ± 1.2 and 2.3 ± 1.3 respectively) compared to eyes from animals
fed with WT leaf (EAU grade, 3.4 ± 0.53) (Figure 6b).
The uveoretinitis was also evaluated by OCT imaging on day 14
after immunization with IRBP. In few cases, severe retinal pathology
such as high level of cellular infiltration, edema, folds, and hemorrhages limited OCT resolution of retinal layers. In most cases, intravitreal cellular infiltration, retinal vasculitis, disorganized retinal

a

WT leaf fed

layers and increased retinal thickness due to retinal folds and edema,
can be easily visualized with OCT imaging as shown in Figure 7a
in untreated or WT leaf material treated animals, these pathologies are much improved in mice treated with CTB-ACE2 or Ang(1–7) (Figure 7a). Treatment with CTB-ACE2 or CTB-Ang-(1–7)
leaf materials significantly reduced EAU-induced increased retinal
thickness (269 ± 32 µm and 241 ± 52 µm respectively) compared to
eyes treated with WT leaf (316 ± 32 µm) (Figure 7b).

Oral administration of CTB-ACE2 and CTB-Ang-(1–7)
ameliorates histological findings in the EAU mice
Histological examination on day 14 showed a severe intraocular
inflammation evidenced by massive infiltration of inflammatory
cells, intensive retinal vasculitits, and changes in the retinal thickness, folding of retina, as well as photoreceptor damage in the WT
leaf fed mice (Figure 8a). However, only scattered inflammation
of inflammatory cells and minor retinal folding was observed
in CTB-ACE2 or CTB-Ang-(1–7) treated animals (Figure 8a).
Histopathological grading, using the criteria reported by Thurau
et al.29 showed that WT leaf fed eyes (EAU grade, 2.95 ± 0.717)
had significantly severe inflammation as compared to CTB-ACE2
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Figure 6 Clinical evaluation of EAU from fundoscopic photographs. EAU was induced in B10.RIII mice by immunization with IRBP in CFA. The fundoscopic images were obtained on day 14 after immunization. (a) Representative fundus image from (i,ii) WT leaf fed mice; (iii,iv) CTB-ACE2 expressed leaf
fed mice; and (v,vi) CTB-Ang-(1–7) expressed leaf fed mice. (b) Clinical EAU scores. Clinical EAU score was evaluated on a scale of 0–4. Values on y-axis
represent the average of clinical scores given on fundus images. Results are given as mean + SD; (n = 5 per group); *P < 0.05 (versus WT fed group).
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feeding was delayed to day 5 and day 10 after EAU induction,
and continued to day 14 when mice were euthanized for evaluation (Supplementary Materials and Methods). We observed
that feeding from day 5 onward up to day 14 after IRBP injection
is equally as effective as feeding from day 0, but feeding started at
10 after EAU induction had no improvement of ocular pathology
(Supplementary Figure S2).

EAU + WT leaf fed
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Non-EAU control
EAU + WT leaf
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Figure 7 Assessment of retinal thickness on OCT images from EAU
mice. Horizontal and cross sectional OCT images were obtained on day
14 after immunization. The retinal thickness was measured and averaged
from five different frames of horizontal OCT scan images of single eye.
(a) Representative fundus projection (left panel) and B-scan (right panel)
images from WT leaf fed mice; CTB-ACE2 expressed leaf fed mice; and
CTB-Ang-(1–7) expressed leaf fed mice. (b) Retinal thickness measured
from OCT images. Values on y-axis represent the average of retinal thickness calculated manually from B-scan OCT images. Results are given as
mean + SD; (n = 5 per group); *P < 0.05 (versus WT fed group).

(EAU grade, 1.1 ± 0.616) and CTB-Ang-(1–7) (EAU grade,
0.92 ± 0.535) expressed leaf fed eyes (Figure 8b). Similarly, significantly higher numbers of inflammatory cells were observed
in the posterior chamber of WT leaf fed mice compared to the
CTB-ACE2/Ang-(1–7) expressed leaf fed mice (Figure 8b).
To determine whether CTB-Ang-(1–7) treatment can also
improve EAU after its onset or during its progression, daily oral
Molecular Therapy vol. 22 no. 12 dec. 2014

In this study, we have developed an expression system to generate
high levels of human ACE2 and Ang-(1–7) within plant chloroplasts using transplastomic technology. Oral gavage of plant cells
expressing ACE2 and Ang-(1–7) fused with CTB in mice resulted
in increased circulating and retinal levels of ACE2 and Ang-(1–7),
reduced ocular inflammation in two different models: endotoxininduced uveitis (EIU) and autoantigen induced experimental
autoimmune uveoretinitis (EAU).
Among many advantages of transplastomic technology, the
high copy number of a transgene, up to >10,000 copies per cell,
is a key to successful high level production of therapeutic proteins in chloroplasts. However, this advantage could be limited
when human transgenes are not codon-optimized because the
preference of codon usage of chloroplast is different from that of
eukaryotic cell. The codon adjustment for chloroplast expression
system is crucial for the efficient expression of human genes.30 So,
the relatively low expression ACE2 over the Ang-(1–7) is probably
due to the use of native human gene sequence (805 amino acids).
However, several other tools were incorporated into our system to
offset low expression of the transgenes so that the contents of therapeutic proteins expressed in chloroplasts can be increased. For
example, the expression of therapeutic proteins under the control
of light-regulated strong chloroplast promoter, harvest of mature
leaves at the end of day, and lyophilization of the harvested leaves.
The chloroplast psbA promoter is light regulated and therefore harvesting leaves expressing therapeutic proteins before sunset maximizes the accumulation of therapeutic proteins. Moreover, the
amount of therapeutic proteins in plant leaves can be concentrated
by lyophilization (Figure 2c,d). The lyophilized therapeutic leaves
need to be powdered and capsulized in clinical use for oral delivery
and long-term storage. The process of dehydration of the leaves
under vacuum at −51 °C for 3 days can significantly reduce the risk
of microbial contamination.11 The long-term shelf life of the lyophilized proteins at room temperature, up to 15 months,11 can also
decrease the cost associated with the cold chain of current injectable proteins.11 The effect of lyophilization on the stability of proteins expressed in chloroplasts has been extensively studied in our
lab under the condition at which temperature and pressure were
set up at −51 °C and 27 mTorr, respectively, according to the chart
of vapor pressure of ice provided by manufacturer. When the effect
of duration of lyophilization was investigated, large protective antigen (PA, 83 kDa) expressed in lettuce chloroplasts was stable at
24, 48, and 72 hours of lyophilization. In addition, the lyophilized
antigen was more stable at room temperature than the commercially purified antigens stored at low temperatures. Furthermore,
the lyophilized PA was found to be stable up to 15 months at room
temperature without any degradation.11 Other transplastomic
plants expressing CTB-exendin 4 (ref. 18) and CTB-Factor VIII31
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Figure 8 Histological evaluation of EAU. (a) Representative micrographs from animals fed with WT leaf fed mice, CTB-ACE2, and CTB-Ang-(1–7)
leaf materials. Left panel: magnifications 40×, scale bar = 200 µm; right panels: 200×, scale bar = 50 µm. Images of histological analysis show severe
retinal folding, loss of the photoreceptor layer and massive inflammatory cell inflammation in the vitreous, retina and subretinal space in WT leaf
fed group; moderate to minimum infiltration, photoreceptor damage, retinal folding was observed in CTB-ACE2 expressed leaf fed group; a minor
infiltration of cells and retinal folding was observed in the CTB-Ang-(1–7) leaf fed group. (b) Histopathology scores. CTB-ACE2 and CTB-Ang-(1–7)
leaf fed groups showed a reduced EAU histological grade compared to controls fed with WT leaf. (c) Evaluation of infiltrating inflammatory cells in
the posterior chamber. Inflammatory cells/section in the posterior chamber were counted on 14th day after EAU induction. Values on y-axis represent
no. of infiltrating inflammatory cells/section. Results are given as mean + SD; (n = 5 per group); *P < 0.05 (versus WT leaf fed group).

showed similar stability of fusion proteins and protection of their
assembly, folding and disulfide bonds similar to fresh leaves.
Drug delivery to different compartments of the eye, particularly
to the posterior segment of the eye, is a major challenge due to several barriers formed by both anatomical structure and the protective physiological mechanisms of the eye.10 Large molecular weight
therapeutics such as peptides/proteins and oligonucleotides are
delivered mostly via intravitreal route. However, frequent administration via this route is often associated with many complications
2078

such as retinal detachment, endophthalmitis, and increased intraocular pressure.32,33 We demonstrate that oral administration of
CTB-ACE2 increased ACE2 activity in sera and retina. Similarly
increased level of plasma and retinal Ang-(1–7) was observed when
the animals were orally administered with CTB-Ang-(1–7), as
observed in previous study of oral delivery of bioencapsulated proteins across blood-brain and retinal barriers.23 The increased level
of the Ang-(1–7) could be stemmed from the fusion with CTB. The
short peptide of Ang-(1–7) fused to CTB becomes stabilized in a
www.moleculartherapy.org vol. 22 no. 12 dec. 2014
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form of pentameric structure in plant cells (Figure 2a). However,
only monomers are observed in sera once delivered into circulation. Considering that the efficiency of furin cleavage site depends
on the flanking amino acid sequence of the fused protein,34 Ang(1–7) fusion to CTB did not offer optimal furin cleavage site. Thus,
the cleavage between CTB and Ang-(1–7) is not likely to be fast or
efficient once the fusion protein gets into sera. In addition, the CTB
fusion provides N-terminal protection for Ang-(1–7) so its stability is extended for several hours, while injectable Ang-(1–7) has a
very short half-life in sera.35,36 Although the Ang-(1–7) level was
increased in both plasma and retina (Figure 3d), the level of Ang(1–7) increase in plasma was less than in retina (Figure 3d). This
difference could be attributed to the increased retention in tissues
(cells) and to their rapid clearance in the sera by proteases. Similar
result was also observed in our previously published study in which
GFP level was shown several fold higher in tissues than in sera.23
Although EIU was originally used as a model of anterior uveitis because of its characteristic infiltration of leucocytes into the
anterior chamber of the eye,4 growing evidences suggest that it
also involves inflammation in the posterior segment of the eye,
with recruitment of leucocytes that adhere to the retinal vasculature and infiltrate the vitreous cavity.3 Our results demonstrate
that enhanced level of ACE2/Ang-(1–7) in both circulation and
ocular tissues suppressed the endotoxin-induced ocular inflammation, which is evident from significantly reduced number of
infiltrating inflammatory cells in the iris-ciliary body, anterior and
posterior chambers. This result is consistent with studies showing anti-inflammatory property of ACE2/Ang-(1–7) in other disease models.7 The dose dependent study using bio-encapsulated
lyophilized CTB-ACE2 in EIU model further confirmed that a
dose of ~50 mg/day for four days can significantly prevent the
endotoxin-induced inflammation. We also showed that increased
ACE2/Ang-(1–7) significantly suppressed the LPS-induced ocular
expression of IL-6, IL-1β, TNF-α, and VEGF. It has been reported
that in EIU model, leucocytes are markedly attracted to inflamed
ocular tissues such as the iris,37 vitreous cavity38 and retina,39 with
neutrophils and macrophages being major leucocyte constituents.
MCP-1 is known as one of the important factors for leucocyte
recruitment, and is up-regulated during EIU40 whereas ICAM-1 is
known to be the key molecule of leucocyte adhesion and/or transmigration.41 Our study demonstrates that mice fed with ACE2/
Ang-(1–7) leaf materials showed decreased ocular expression of
MCP-1 and ICAM-1 in EIU eyes, contributing to the diminished
inflammatory response by inhibiting leucocyte recruitment and
adhesion in the ocular tissue. These results are consistent with the
histopathology observation that LPS-induced acute inflammation caused the increase of inflammatory cell recruitment, while
ACE2/Ang-(1–7) treatment significantly reduced the inflammatory cells in iris/ciliary body, anterior and posterior chamber.
It has been shown that ACE2/Ang-(1–7) may directly reduce
inflammatory responses in immune cells such as macrophages.42
Our study also shows modulatory ability of ACE2/Ang-(1–7)
on local immune response and cytokine/chemokine expression.
In fact, the Mas receptor is expressed not only in retinal vascular cells, astrocytes and muller glia, but also in retinal neurons,
consistent with its role in neuro-vascular and immune response
modulation. Moreover, our results show that eyes with EIU are
Molecular Therapy vol. 22 no. 12 dec. 2014
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associated with decreased expression of ACE2 and Mas receptor and increased expression of vasoconstrictive axis genes
such as ACE, AT1Ra, AT1Rb during EIU. This is prevented by
ACE2/Ang (1–7), suggesting that the anti-inflammatory effect
of ACE2/Ang-(1–7) may be associated with Mas receptor and
ACE2 up-regulation, and down-regulation of ACE and AT1Ra/
AT1Rb, resulting in reduction of ocular inflammation.
In this study, we also investigated the effect of oral administration of CTB-ACE2/Ang-(1–7) on the development of EAU in
mice and showed significant improvement of EAU eyes in mice
treated with CTB-ACE2/Ang-(1–7). The pathogenesis of EAU is
different from EIU. EAU is defined primarily as posterior segment
disease as the target antigens reside in the retina and characterized
by cellular infiltrates, retinal folds, detachment, granulomatous
infiltrates in the retina and choroid, vasculitis, retinal neovascularization, mild to severe photoreceptor loss.29 Histopathological
examination confirmed a significant overall reduction of disease
severity in the CTB-ACE2/Ang-(1–7) treatment groups evaluated by non-invasive funduscopy and OCT imaging methods.
Furthermore, the retinal detachment, photoreceptor layer damage, infiltration of inflammatory cells was markedly prevented
by CTB-ACE2/Ang-(1–7) treatments. Some of the fundoscopically normal-looking eyes showed few foci of very mild cellular
infiltrates on histological evaluation. This is consistent with the
findings from OCT imaging, demonstrating a better correlation of histological findings and pathological changes revealed
by non-invasive OCT imaging in the retina during EAU. Thus,
oral administration of CTB-ACE2/Ang-(1–7) from the induction
to peak of EAU was able to ameliorate the progression of disease
evaluated by clinical funduscopic score, OCT imaging and histopathological observation. Moreover, delayed oral administration
of CTB-ACE2/Ang-(1–7) from day 5 after EAU induction was
also able to decrease the progression of EAU.
Increasing evidence has shown that shifting the balance of RAS
towards the protective axis by activation of ACE2 or its product, Ang(1–7) is beneficial and anti-inflammatory.7,43 Our findings also demonstrate that oral administration of CTB-ACE2/Ang-(1–7) provides
robust protective anti-inflammatory effects against the pathophysiology in both EIU and EAU models. Nevertheless, future studies to
further elucidate the molecular and cellular mechanisms underlying
the anti-inflammatory effects of Ang-(1–7) and ACE2, to further
define the pharmacokinetics and potential impact on other tissues/
organs following oral administration will be essential for clinical
applications. The recombinant CTB has already been approved for
human use a decade ago and is used by hundreds of millions of
people around the globe.44 There are several studies using CTB to
induce immune tolerance by orally administered human proteins
conjugated to CTB, which would be an added advantage for prolonged use of this protein for treatment. For instance, the symptoms
of autoimmune diseases including diabetes,16 arthritis,45 uveitis,46
and hemophilia19,31 have been shown to be prevented or delayed.
The successful induction of oral tolerance by CTB-autoantigen conjugates in experimental systems has been also proven in pilot clinical trials;47 CTB-BD peptide treatment blocked relapse of uveitis
and recurrence of uveitis for 10–18 months after cessation of treatment.47 Therefore, we anticipate development of human ACE2 and
Ang-(1–7) fused form to CTB would progress smoothly.
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In conclusion, this study provides proof-of-concept for production of therapeutically active ACE2/Ang-(1–7) bioencapsulated in
plant cells for cost effective oral therapy for ocular applications and
enhancing ACE2/Ang-(1–7) using this approach may provide a
new avenue and a novel therapeutic strategy for the treatment of
acute uveitis, autoimmune uveoretinitis and other ocular diseases.

MATERIALS AND METHODS
Chloroplast transformation vector construction and regeneration of
transplastomic lines. The cDNA for ACE2 (accession: NM_021804) was

used as the template to clone CTB-ACE2 fusion gene into the intermediate vector. To clone CTB-Ang-(1–7) fusion gene, CTB-containing vector
was used as template with a forward primer specific to CTB and a reverse
primer specific to CTB but including nucleotide sequence corresponding
to 7 amino acid of Ang-(1–7) peptide. The sequence-confirmed chimeric
gene was cloned into chloroplast transformation vector, pLD. Delivery of
the fusion genes into chloroplast genome, regeneration of transplastomic
plants, and PCR analysis of the specific integration of the transgene were
carried out according to the previously published methods.48
Western blot analysis and quantification. Western blot and densitometric
analysis were performed for the quantification of CTB-Ang-(1–7). Total leaf
protein and purified CTB standard protein (Sigma-Aldrich, St Louis, MO)
were separated on SDS-polyacrylamide gel and transferred to nitrocellulose
membranes. Rabbit anti-CTB polyclonal antibody (GenWay Biotech, San
Diego, CA) was used to probe the fusion proteins and then the developed
films were scanned for quantitative analysis using Image J (IJ 1.46r; NIH)
software. Standard curve was created using the known amounts of CTB
standard and then the protein samples were interpolated on the graph.
ELISA was performed to quantify CTB-ACE2 protein. Serially diluted
CTB and CTB-ACE2 in bicarbonate buffer were used for coating 96-well
plates. The rabbit anti-CTB polyclonal antibody and goat anti-rabbit IgGHRP antibody (Southern Biotechnology, Birmingham, AL) was used for
immunodetection. Tetramethylbenzidine (TMB) was used as substrate
(American Qualex Antibodies, San Clemente, CA) for the peroxidase and
the color change was read spectrophotometrically at a wavelength of 450 nm.
For in vivo protein sample analysis, western blotting was performed
with rabbit anti-CTB (Abcam, Cambridge, MA) and rabbit anti-ACE2
(Santa Cruz Biotechnology, Dallas, TX), and mouse β-actin antibodies
(Sigma-Aldrich) and bound antibody detected using Odyssey imaging
system (Li-Cor, Lincoln, NE).
CTB-GM1 binding assay. The formation of pentameric structure of CTB
fused therapeutic proteins expressed in chloroplasts was investigated using
CTB-GM1 ELISA method described earlier.23 Monosialoganglioside-GM1
(Sigma-Aldrich, G-7641) coated ninety-six-well plates were incubated
with homogenate plant proteins, which were serially diluted up to 10
pg/µl, at 4 °C, along with purified CTB and untransformed WT plant protein (10 ng/µl) as positive and negative control, respectively. After washing the plates thrice with 1X phosphate buffered saline with 0.05% (v/v)
Tween-20 (PBST), the plate was blocked with 1X PBST (0.05% Tween 20)
with 3% non-fat dry milk (PTM) for 1 hour at 37 °C. To detect the interaction between CTB pentamer and GM1, anti-CTB antibody (1:10,000
in PTM; GenWay Biotech) and IgG-HRP secondary antibody (1:4,000
in PTM; Southern Biotechnology) were used. The binding affinity was
quantitatively analyzed as a function of absorbance at 450 nm using plate
reader (Bio-Rad Life Sciences, Hercules, CA, Model 680) after incubation
with 100 μl of tetramethylbenzidine (TMB) solution substrate (American
Qualex Antibodies, San Clemente, CA). An absorbance of ≥ 0.1 after
background signal substraction was determined as positive.
Lyophilization. The harvested leaves from greenhouse were rinsed with
water then frozen in liquid nitrogen, and crumbled into small pieces. For
freeze-drying, containers were sealed with porous 3M Millipore Medical
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Tape and then lyophilized in VirtisBenchtop Freeze Dry Systems (SP
Scientific, Gardiner, NY) Lyophilized leaf material was ground into fine
powers using ordinary coffee grinder and stored in sealed container at
room temperature with silica gel until use.
Animals and experimental procedures. WT C57Bl/6J mice (6–8 weeks

old) and B10.RIII mice (8–10 weeks old) were purchased from Jackson
Laboratories (Bar Harbor, ME) and maintained at the Animal Care Service
at the University of Florida. All procedures adhered to the ARVO statement for the use of Animals in Ophthalmic and Vision Research, and the
protocol was approved by the Animal Care and Use Committee of the
University of Florida. The animals were fed standard laboratory chow
and allowed free access to water in an air-conditioned room with a 12–
12-hours light–dark cycle.
The mice were divided in three groups for EIU model and orally
gavaged with control (untransformed WT) tobacco leaves, CTB-ACE2,
and CTB-Ang-(1–7) expressing transplastomic tobacco leaves. The mice
were given ~500 mg of the specified tobacco leaf material suspended
in sterile PBS, by careful gavage into the hypopharynx twice in a day
for 5 days. For preparation of the gavage material, leaves were frozen
and ground in liquid nitrogen. EIU was induced by a single intravitreal
injection of Escherichia coli LPS (25 ng/eye) (Sigma-Aldrich) dissolved in
sterile pyrogen-free saline, on the fifth day of feeding. All animals were
anesthetized and pupils were dilated before intraocular injections. Each
experimental group included at least 4–6 animals and each experiment
was performed at least twice.
For the EAU model, the mice were divided in three groups and orally
gavaged with ~500 mg of the control WT tobacco leaves, CTB-ACE2,
CTB-Ang-(1–7) expressing transplastomic tobacco leaves once daily for
15 days. EAU was induced by active immunization with ~50 µg of IRBP
(161–180) (SGIPYIISYLHPGNTILHVD) (Genscript, Piscataway, NJ)
with CFA (Sigma-Aldrich) (1:1 vol/vol) subcutaneously, on the second
day of feeding. Each experimental group included at least four to six
animals and each experiment was performed at least twice to ensure
reproducibility.

Histopathological evaluation. The EIU mice were euthanized 24 hours
after LPS injection and the eyes were enucleated immediately and fixed
in 4% paraformaldehyde freshly made in PBS overnight at 4 °C and processed for paraffin embedding and sections. Sagittal sections (4 µm) from
every 50 µm were cut and stained with hematoxylin and eosin (H&E). The
anterior and posterior chambers were examined under light microscope
and the infiltrating inflammatory cells were counted in a masked fashion.
The number of infiltrating inflammatory cells in five sections per eye was
averaged and recorded. EIU clinical data shown were representatives of
three sets of experiments.
The EAU mice were euthanized and the eyes were harvested on 14th
day after immunization, followed by fixation, paraffin embedment and
stained with H&E. The severity of EAU was evaluated in a masked fashion
on a scale of 0–4 using previously published criteria based on the number,
type and size of lesions29 and the inflammatory cells were counted as
described above. EAU clinical data shown were representatives of two sets
of experiments, five animals each experimental group.
ACE2 activity assay. Representative retinas from each group of mice were

dissected and homogenized by sonication in ACE2 assay buffer. The ACE2
activity assay was performed using 100 µg of retinal protein in black 96-well
opaque plates with 50 µmol/l ACE2-specific fluorogenic peptide substrate
VI (R&D Systems, Minneapolis, MN) in a final volume of 100 µl per well
reaction mixture. The enzymatic activity was recorded in a SpectraMax M3
fluorescence microplate reader (Molecular Devices, LLC, Sunnyvale, CA)
for 2 hours with excitation at 340 nm and emission at 400 nm as described
previously.8 For the sera samples, 10 µl sera were used in a 100 µl reaction.
All measurements were performed in duplicate and the data represent the
mean of three assay results.
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Table 1 Primers used for real-time RT-PCR analysis
Gene name

Accession
number

Interleukin-6

NM_031168.1

Sequences

Forward:
5’-TCGGCAAACCTAGTGCGTTA -3’
Reverse:
5’-CCAAGAAACCATCTGGCTAGG-3’

IL-1β

NM_008361.3

Forward:
5’-AAAGCCTCGTGCTGTCGGACC -3’
Reverse:
5’-CAGCTGCAGGGTGGGTGTGC -3’

TNF-α

NM_013693.2

Forward:
5’-AGGCGCCACATCTCCCTCCA-3’
Reverse:
5’-CGGTGTGGGTGAGGAGCACG-3’

ICAM-1

NM_010493

Forward:
5’-AGATGACCTGCAGACGGAAG-3’
Reverse:
5’-GGCTGAGGGTAAATGCTGTC-3’

MCP-1

NM_011333

Forward:
5’-CCCCACTCACCTGCTGCTACT-3’
Reverse:
5’-GGCATCACAGTCCGAGTCACA-3’

β-Actin

X03672

Forward:
5’-AGCAGATGTGGATCAGCAAG-3’
Reverse:
5’-ACAGAAGCAATGCTGTCACC-3’

MAS receptor

NM_008552

Forward:
5′-AGGGTGACTGACTGAGTTTGG-3′
Reverse:
5′-GAAGGTAAGAGGACAGGAGC-3′

AT1Ra

NM_177322

Forward:
5’-ATCGGACTAAATGGCTCACG-3’
Reverse:
5’-ACGTGGGTCTCCATTGCTAA-3’

AT1Rb

AK087228

Forward:
5’-AGTGGAGTGAGAGGGTTCAA-3’
Reverse:
5’-GGGCATTGAAGACATGGTAT-3’

Ang-(1–7) estimation by enzyme immunoassay. The level of Ang-(1–7)
in plasma and retina were measured using a commercial EIA kit (Bachem,
San Carlos, CA), according to the manufacturer’s instructions. All measurements were performed in duplicate and the data represent the mean of
two separate assay results.
Real time RT-PCR analysis. Total RNA was isolated from freshly enucle-

ated eyes using Trizol Reagent (Invitrogen, Carlsbad, CA) according to
manufacturer’s instructions. Reverse transcription was performed using
Enhanced Avian HS RT-PCR kit (Sigma-Aldrich) following manufacturer’s instructions. Real time PCR was carried out on real time thermal
cycler (iCycler, Bio-Rad Life Sciences) using iQTMSybr Green Supermix
(Bio-Rad Life Sciences). The threshold cycle number (Ct) for real-time
PCR was set by the cycler software. Optimal primer concentration for PCR
was determined separately for each primer pair. Each reaction was run
in duplicate or in triplicate, and reaction tubes with target primers and
those with Actin primers were always included in the same PCR run. To
test the primer efficiencies, the one-step reverse-transcriptase-PCR was
run with each target primer. Relative quantification was achieved by the
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comparative 2−ΔΔCt method 1. The relative increase/decrease of mRNA
target X in the experimental group (EG) was calculated using the control
group as the calibrator: 2−ΔΔCt, where ΔΔ Ct is {Ct. × [EG] − Ct. Actin [EG]}
− {Ct. × [control] − Ct. Actin [control]}. Primer sequences used in this
study are shown in Table 1. All the reactions were repeated at least twice.
Fundus imaging and assessment of EAU. Fundus assessment of EAU was

performed at day 14 after EAU induction. The pupils were dilated using
atropine sulfate and phenylephrine hydrochloride. The mice were anesthetized by intraperitoneal injection of ketamine (75 mg/kg) and xylazine
(5 mg/kg) mixture, and GonakHypromellose demulcent ophthalmic solution (Akorn, Buffalo Grove, IL) was used on ocular surface. The fundus
was imaged using the Micron II small animal retinal imaging AD camera
(Phoenix Research Laboratories, Pleasanton, CA). Eyes were examined
for vasculitis, focal lesions, linear lesions, retinal hemorrhages and retinal
detachment. Clinical EAU scoring was performed on a scale of 0–4, as
described in detail previously.28 EAU clinical data shown was representative of two sets of experiments.

Spectral Domain Optical Coherence Tomography imaging and assessment of EAU mice. Mice were anesthetized and the pupil dilated as

described above. Artificial tears (Systane Ultra, Alcon, Fort Worth, TX)
were used throughout the procedure to maintain corneal moisture and clarity. Spectral Domain Optical Coherence Tomography (SD-OCT) images
were obtained in mice on 14th day after immunization using the Bioptigen
Spectral Domain Ophthalmic Imaging System (Bioptigen, Durham, NC).
Images acquired by the software provided from the company. The average
single B scan and volume scans were obtained with images centered on
optic nerve head. The retinal thickness was measured from five frames of
the volume of OCT images and averaged from the intensity peak of boundary corresponding to the vitreo-retinal interface to the intensity peak corresponding to the retinal pigmented epithelium.49 EAU clinical data shown
was representative of two sets of experiments.

Statistical analysis. Data are expressed as the mean + SD of at least two
independent experiments. Differences between mean values of multiple
groups were analyzed by one-way analysis of variance with Dunnett’s test
for post hoc comparisons. A P value less than 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIAL
Figure S1. Histological evaluation of EIU mice. The mice were orally
administered with different doses of lyophilized plant cells expressing
CTB-ACE2 for 4 days before LPS(25ng/eye)injection.
Figure S2. Evaluation of EAU from fundoscopic photographs, OCT
and histopatholgy. EAU was induced in B10.RIII mice by immunization
with IRBP in CFA.
Materials and Methods.
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